Investigating Trends in Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Treatment with Nintedanib (QUALIFY IPF)

08/10/2018
19/10/2026
EU PAS number:
EUPAS25664
Study
Finalised
Study type

Study topic

Disease /health condition
Human medicinal product

Study type

Non-interventional study

Scope of the study

Evaluation of patient-reported outcomes
Other

If ‘other’, further details on the scope of the study

QoL evaluation

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Medicinal product name

Study drug International non-proprietary name (INN) or common name

NINTEDANIB

Anatomical Therapeutic Chemical (ATC) code

(L01XE31) nintedanib
nintedanib

Medical condition to be studied

Idiopathic pulmonary fibrosis
Population studied

Short description of the study population

Patients with IPF Under Treatment with Nintedanib

Age groups

  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)

Estimated number of subjects

240
Study design details

Study design

National, multicentre, non-interventional, prospective cohort study

Main study objective

To evaluate the HRQoL changes of IPF patients treated in current clinical practice in Greece with nintedanib over a 52-weeks period

Setting

Data of 180 newly diagnosed IPF patients enrolled from 10 University Pulmonology Clinics and Reference Centres of the Public Hospital Setting across Greece were collected. Hospital Pulmonary Clinics acted as coordinating sites of the study. All included sites were reference centres for IPF, both in Athens and the rest of Greece, so that patients enrolled would constitute a representative population of IPF patients in Greece.

Outcomes

Mean change from baseline in HRQoL in patients under treatment with nintedanib over 52 weeks follow-up period, Change from baseline of dyspnoea burden as measured by mMRC questionnaire Mean change from baseline of cough burden as measured by the cough - VAS Percentage of adhered patients to nintedanib treatment Mean change from baseline of anxiety as measured by the GAD-7 questionnaire. Percentage of patients that use LTOT over the 52 weeks follow up period

Data analysis plan

The nature of the statistical analyses will be exploratory and descriptive.

Summary results

In conclusion, in the QUALIFY study, newly diagnosed IPF patients being treated with nintedanib under real-life conditions showed deterioration in the overall self-reported HRQoL, in line with the progressive nature of the
disease Moreover, no apparent effect on the delay of deterioration was implicated in the overall HRQoL, except from a modest effect in the symptoms burden. Nevertheless, future analyses designed based on the patients’ disease clinical characteristics including severity at baseline as well as disease progression over time upon treatment with nintedanib may help to further elucidate nintedanib’s potential effect on the HRQoL of
patients with IPF.